2-氯-3-氯甲基吡啶 | 89581-84-0

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-氯-3-氯甲基吡啶
• 中文别名: 2-溴-3-(氯甲基)吡啶
• 英文名称: 2-chloro-3-(chloromethyl)pyridine
• 英文别名: 2-chloro-pyridin-3-ylmethyl chloride
• CAS: 89581-84-0
• 化学式: C₆H₅Cl₂N
• mdl: MFCD09835107
• 分子量: 162.018
• InChiKey: QWIIJVGEBIQHSW-UHFFFAOYSA-N

物化性质

• 沸点：
  250℃
• 密度：
  1.324
• 闪点：
  129℃

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2933399090
• 包装等级：
  II
• 危险类别：
  8
• 危险性防范说明：
  P501,P260,P264,P280,P303+P361+P353,P301+P330+P331,P363,P304+P340+P310,P305+P351+P338+P310,P405
• 危险品运输编号：
  3261
• 危险性描述：
  H314
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Chloro-3-(chloromethyl)pyridine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Chloro-3-(chloromethyl)pyridine
CAS number: 89581-84-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H5Cl2N
Molecular weight: 162.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氯-3-氯甲基吡啶 在 水 、 sodium hydroxide 作用下， 以 水 为溶剂， 反应 5.5h， 生成 2-氯-3-吡啶甲醇
  参考文献：
  名称：

  一种2-氯-3-吡啶甲醛的合成方法

  摘要：

  本发明公开了一种2‑氯‑3‑吡啶甲醛的合成方法，该方法以2‑氯‑3‑甲基吡啶为原料，依次经过氯气氯化、酯化水解、氧化三步得到2‑氯‑3‑吡啶甲醛产品。本发明方法反应条件温和，收率高，成本低，产品纯度达98％以上，具有较好的工业应用前景。

  公开号：

  CN107501171B
• 作为产物：
  描述：

  2-氯-3-吡啶甲醇 在 吡啶 、 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 以100%的产率得到2-氯-3-氯甲基吡啶
  参考文献：
  名称：

  杂环化中的分子内N-芳基化：新型吡啶基稠合的吡咯并[1,2- a ] [1,4]二氮杂pin酮的合成

  摘要：

  将1-脯氨酰胺与3-（氯甲基）-2-卤代吡啶烷基化，然后通过分子内Pd催化的酰胺化反应进行环化，从而提供了吡啶并[2,3- e ]吡咯并[1,2- a ] [1 ，4] diazepin-10-1支架。此外，通过用Boc-1-脯氨酸对连续取代的（氨甲基）卤代吡啶进行酰化，然后再用Boc-1-脯氨酸进行酰化反应，从而开发了一条合成途径，用于合成各种新的吡啶并[ f ]吡咯并[1,2- a ] [1,4]二氮杂-7-酮。分子内胺化。

  DOI：

  10.1016/j.tetlet.2010.05.121

文献信息

• HETEROBICYCLIC COMPOUNDS
  申请人：Amgen Inc.

  公开号：US20130225552A1

  公开（公告）日：2013-08-29

  Heterobicyclic compounds of Formula (I): or a pharmaceutically-acceptable salt, tautomer, or stereoisomer thereof, as defined in the specification, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, Huntington's Disease, and the like.

  Formula (I)的杂环化合物： 或其药用可接受的盐、互变异构体或立体异构体，如规范中所定义，并含有它们的组合物，以及制备这种化合物的方法。本文还提供了通过抑制PDE10来治疗由此可治疗的疾病或疾病的方法，如肥胖症、非胰岛素依赖型糖尿病、精神分裂症、躁郁症、强迫症、亨廷顿病等。
• NOVEL TRICYCLIC DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
  申请人：Kim Myung-Hwa

  公开号：US20110218193A1

  公开（公告）日：2011-09-08

  The present invention relates to a novel tricyclic derivative with efficient inhibitory activity against poly(ADP-ribose)polymerases (PARP) or pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition containing the same. The tricyclic derivative of the invention is useful for the prevention or treatment of diseases caused by excess PARP activity, especially neuropathic pain, neurodegenerative diseases, cardiovascular diseases, diabetic nephropathy, inflammatory diseases, osteoporosis, and cancer, by inhibiting the activity of poly(ADP-ribose)polymerases.

  本发明涉及一种新型三环衍生物，具有高效的抑制聚(ADP-核糖)聚合酶（PARP）或其药用可接受盐的活性，以及其制备方法和含有该衍生物的药物组合物。本发明的三环衍生物通过抑制聚(ADP-核糖)聚合酶的活性，对于预防或治疗由过度PARP活性引起的疾病特别有效，包括神经病痛、神经退行性疾病、心血管疾病、糖尿病肾病、炎症性疾病、骨质疏松症和癌症。
• Process for the Synthesis of Aminobiphenylene
  申请人：Heinrich Markus

  公开号：US20130338369A1

  公开（公告）日：2013-12-19

  The present invention relates to a process for the synthesis of 2-aminobiphenylene and derivatives thereof by reacting a benzene diazonium salt with an aniline compound under basic reaction conditions.

  本发明涉及一种通过在碱性反应条件下将苯重氮盐与苯胺化合物反应合成2-氨基联苯及其衍生物的方法。
• [EN] THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS<br/>[FR] DÉRIVÉS DE THIÉNO-PYRIDINE UTILISÉS COMME INHIBITEURS DE MEK
  申请人：UCB PHARMA SA

  公开号：WO2009153554A1

  公开（公告）日：2009-12-23

  A series of thieno[2,3-6]pyridine derivatives, attached at the 2-position to a substituted anilino moiety, which are substituted in the 3-position by a carbonyl group linked to a pyrrolidin-1-yl ring which in turn forms part of a heteroatom-containing fused bicyclic ring system, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.

  一系列噻吩[2,3-6]吡啶衍生物，连接在取代苯胺基团的2-位置，其在3-位置被一个与吡咯啉-1-基环相连的羰基取代，后者又构成一个含杂原子的融合双环环系统的一部分，是人类MEK（MAPKK）酶的选择性抑制剂，在医学上具有益处，例如在治疗炎症、自身免疫、心血管、增殖（包括肿瘤学）和疼痛性疾病方面。
• [EN] PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF VOXELOTOR<br/>[FR] PROCÉDÉ ET INTERMÉDIAIRES POUR LA SYNTHÈSE DE VOXÉLOTOR
  申请人：BIONICE S L U

  公开号：WO2020127945A1

  公开（公告）日：2020-06-25

  The invention relates to a process for the preparation of Voxelotor, or a salt or solvate thereof, according to the following scheme (Formula 1).

  这项发明涉及根据以下方案（公式1）制备Voxelotor或其盐或溶剂的过程。